Overview

Gender

male

Mr. Cannon has over forty years experience in the pharmaceutical industry. He worked for twenty years at SICOR a Swiss-Italian API manufacturing company in a variety of positions in manufacturing, quality and regulatory affair before moving to business development.

He was a member of the team that conducted the merger of SICOR with Gensia of San Diego in 1997. He served as a member of SICOR’s board and president of the biotech division until the company was sold to Teva in 2004.

He is now a board member of Waterstone, a Chinese pharmaceutical company; as well as Osel and BioSentinel in the US.